Home >   Products   >  Advanced Search

Olmesartan
(CAS RN:144689-24-7 Product Number:O0507)

Structure

zoom
Olmesartan

General Information

Product Number O0507

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature <0°C
M.F. / M.W. C24H26N6O3=446.51
CAS RN 144689-24-7
Related CAS RN
MDL Number MFCD00914967
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 95.0 %

References

Reaxys-RN 7502669
PubChem SID 354335584
RTECS# NI4014100

Transport Information

HS Number 2933998090

Application

Olmesartan: A Selective AT1 Subtype Angiotensin II Receptor Antagonist (“sartan”)

Olmesartan, an active metabolite of olmesartan medoxomil [O0510], is a selective AT1 subtype angiotensin II receptor antagonist (“sartan”), such as candesartan [C2635], eprosartan [E1161], irbesartan [I0859], losartan [L0232], olmesartan [O0507], telmisartan [T2861] and valsartan [V0112].
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angio-tensin converting angiotensin conversion enzyme (ACE), and can active two different receptors, AT1 and AT2, both of which are coupled to G-protein. The vasopressor actions of angiotensin II are mediated through AT1 receptors. Olmesartan and sartans bind selectively to AT1 receptor with almost no binding to AT2 receptor in vascular smooth muscle. Therefore, olmesartan and sartans show blood pressure lowering effect. Recently, some combination agents with a calcium channel antagonist (e.g. amlodipine [A2353], azelnidipine [A2433]) are also used for the treatment of hypertension and cardiovascular disease. (The product is for research purpose only.)

References

Page Top